Learning Hub

< BACK iPROLEPSIS Website Goes Live Mar 26, 2023 The website of the iPROLEPSIS project is finalised and available online. The website of the iPROLEPSIS project is finalised and available online. The website presents the key facts and figures about the project, and will be frequently updated about the project results, events, and key plans. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK Innovative Digital Solutions for Psoriatic Arthritis: A Spotlight on the iPROLEPSIS Project by Prof. Leontios Hadjileontiadis Feb 14, 2024 Empowering Patients, Pioneering Solutions, and Bridging Gaps in Psoriatic Arthritis Knowledge Prof. Leontios Hadjileontiadis, the coordinator of the iPROLEPSIS project, shares how the iPROLEPSIS project addresses psoriatic arthritis research . iPROLEPSIS aims to identify triggers behind the transition from psoriasis to psoriatic arthritis, employing digital models and everyday devices like smartphones and smartwatches to understand disease dynamics. Beyond research, iPROLEPSIS introduces practical solutions such as biAURA for pain relief through sound and serious games targeting exercise, emotion, nutrition, and pain management. Collaborating with 15 partners, including patient advocates, iPROLEPSIS adopts a co-creation approach , bridging technological innovation with real-world healthcare practices. Focusing on predictive and preventive healthcare, iPROLEPSIS strives to fill the knowledge gap surrounding psoriatic arthritis, transforming the research landscape. Watch the full interview: leontios_edited.jpg leontios_edited.jpg 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Project Presented to Sonova International Sep 10, 2024 Innovative Approaches in Digital Biomarkers In September 2024, the iPROLEPSIS project was presented at a meeting with Sonova International. This event included a series of insightful presentations, highlighting the project's focus on developing digital biomarkers. The iPROLEPSIS concept and vision were shared, showcasing the innovative approaches the project is undertaking. We extend our gratitude for the engaging discussions during the “Sonova-AUTH Day,” hosted by the Signal Processing & Biomedical Technology Unit at Aristotle University of Thessaloniki. The event featured a range of topics, including advancements in digital biomarkers, innovations in hearing instruments by Sonova Group, ear-EEG technology, auditory processing disorders, and insights into the hearing aid market in Greece. 1/2 PREVIOUS NEXT

< BACK Exploring the iPROLEPSIS Project: Insights from J. Luime Sep 17, 2024 Innovative Approaches to Monitoring and Managing Psoriatic Arthritis Jolanda Luime, senior researcher and project partner from Erasmus MC (the Netherlands), shares insights on the iPROLEPSIS project. The iPROLEPSIS project represents a significant advancement in the field of psoriatic arthritis research. By leveraging cutting-edge technology, including smartphones and data analysis, iPROLEPSIS aims to transform how we measure and understand psoriatic arthritis activity. Traditional methods of tracking psoriatic arthritis often fall short in capturing the full scope of the disease’s impact. iPROLEPSIS seeks to address this gap by exploring new and innovative approaches. The project uses advanced technology to monitor movement patterns and other key indicators of disease activity, offering a more comprehensive view of how the condition affects patients on a daily basis. One of the core objectives of iPROLEPSIS is to empower patients with better tools for managing their condition. By providing more detailed insights into disease activity, the project aims to help patients make informed decisions about their health and potentially prevent disease flares before they occur. This proactive approach has the potential to significantly improve the quality of life for those living with psoriatic arthritis. In addition to benefiting patients, iPROLEPSIS aims to to support clinicians by offering more accurate and actionable data. With better insights into disease activity and treatment effectiveness, healthcare providers can make more informed decisions regarding medication adjustments and overall treatment strategies. This not only enhances patient care but also helps streamline clinical practices, making the process more efficient and effective. Through the iPROLEPSIS project, the aim is to provide patients and clinicians with the tools they need to better understand and manage psoriatic arthritis, ultimately improving both patient outcomes and clinical practices. 1/1 PREVIOUS NEXT

< BACK Khalifa University Features iPROLEPSIS in Research News Jun 2, 2025 AI, Apps and Arthritis: A Digital Leap in Psoriatic Care Khalifa University Research News has featured iPROLEPSIS in a new article showcasing our mission to transform psoriatic arthritis care through digital innovation. Led by Prof. Leontios Hadjileontiadis, iPROLEPSIS is a Horizon Europe-funded initiative using artificial intelligence, wearable technology, and mobile health apps to shift care from reactive treatment to proactive prevention . By combining explainable AI with real-world patient data, we aim to support earlier diagnosis , personalized treatment , and patient-centered digital tools that empower both clinicians and individuals living with psoriatic arthritis. Read the full article on Khalifa University website: https://www.ku.ac.ae/ai-apps-and-arthritis-a-digital-leap-in-psoriatic-care Hero section.png Hero section.png 1/1 PREVIOUS NEXT

< BACK Advancing Psoriatic Arthritis: Rheumatologist Ilja Tchetverikov's Insights on iPROLEPSIS May 22, 2024 Exploring Innovative Approaches to Disease Management and Patient Care in Psoriatic Arthritis" Ilja Tchetverikov , a rheumatologist and project partner from the CICERO Foundation (the Netherlands), provides insights into the iPROLEPSIS project's endeavours. He emphasises the need for a deeper understanding of psoriatic arthritis , a chronic inflammatory condition impacting various body parts due to immune system disturbances. I. Tchetverikov highlights the project's focus on investigating disease progression factors and developing non-invasive measurement tools . “Everybody can measure anything, but then you have to know what you're measuring. The whole idea of the project is that we combine two strengths. One of them is providing and developing a technical solution on how to measure the disease activity. And from the other side, we are going to label the data coming in from the system, from the clinical point of view. So we will be able to say whether or not some people have a low or high level of disease activity. So it's one part of the investigation. The other part of the investigation is to see whether other factors, which are already known to influence the whole system of your human body, like stress factors and some, for instance, gut microbiome composition, can also change during the course of the disease and how they are influencing the course of the disease itself,” states Ilja Tchetverikov . Through a collaborative effort integrating clinical expertise and technical innovation, the project aims to assess disease activity levels and explore external factors accurately. iPROLEPSIS interview.png iPROLEPSIS interview.png 1/1 PREVIOUS NEXT

< BACK Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs Feb 5, 2026 New iPROLEPSIS publication presents a smartphone-based approach for remote joint swelling assessment in psoriatic arthritis A new publication from the iPROLEPSIS project has been published in the proceedings of the 2025 IEEE International Conference on E-health Networking, Application & Services (HealthCom) . The study investigates the use of smartphone photographs to support the remote assessment of swollen joints in patients with inflammatory arthritis, focusing on psoriatic arthritis. The proposed method classifies each interphalangeal joint in hand photographs as swollen or not swollen, supporting scalable and patient-friendly monitoring approaches. Read the full publication: https://zenodo.org/records/18481583 iPROLEPSIS_Apostolidis G._HealthCom.png iPROLEPSIS_Apostolidis G._HealthCom.png 1/1 PREVIOUS NEXT

< BACK Initiation of the iPROLEPSIS-PDPID Study Oct 22, 2024 Initiating Patient Enrollment for Psoriatic Arthritis Research The PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID) has officially been initiated. The first patient was enrolled in the Netherlands in early September. The iPROLEPSIS-PDPID study focuses on using smart devices and clinical data to develop AI-driven models for personalised monitoring and flare prediction. This approach aims to empower patients by providing tools to better understand their condition. The study seeks to develop unobtrusive and affordable digital biomarkers capable of detecting changes in disease activity, including flares, and identifying their triggers in patients with psoriatic arthritis (PsA). The study is being conducted in four countries: the Netherlands, the UK, Portugal, and Greece. Patient recruitment is planned to start in the UK by the end of October, with recruitment in Greece and Portugal expected later this year. The miPROLEPSIS phone app is used in this study. The app is installed on patients' smartphones and acts as a data collection tool, which will be used to develop and train algorithms. The app measures physical activity, sleep duration, self-registered flares, and daily records of pain, fatigue, sleep quality, and morning stiffness. Additionally, the Garmin Vivoactive 5 smartwatch is used to collect data on physical activity, heart rate, heart rate variability, and sleep quality. 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 6 Oct 9, 2024 Latest News from iPROLEPSIS Welcome to the 6th edition of the iPROLEPSIS newsletter. In this edition, we share the latest updates and progress from our project, including new developments, recent publications, and reflections on key events. iPROLEPSIS project newsletter_October 2024_ Issue No. 6 .pdf Download PDF • 4.41MB 1/1 PREVIOUS NEXT

< BACK AINIGMA Technologies at InnoHealth Forum 2024 Sep 24, 2024 Highlights from InnoHealth Forum 2024 iPROLEPSIS colleagues from the AINIGMA Technologies team participated in the InnoHealth Forum 2024 (20-21 September, 2024), an event that promotes and highlights innovative health technology solutions for the benefit of humanity. With 25 exhibitors, 50+ live demos of cutting-edge health products and services and over 130 matchmaking meeting and networking opportunities, this forum was a great opportunity to spread the word about the iPROLEPSIS project and connect with potential end-users. 1/5 PREVIOUS NEXT

< BACK State-of-the-art analysis and datasets landscape Nov 6, 2023 Initial review, focusing on the state-of-the-art literature and existing datasets in the field of PsA Psoriatic arthritis is a chronic immune-mediated inflammatory arthritis occurring in patients with PsO. The disease manifestation can be heterogeneous between subjects, and the resulting musculoskeletal impairment can interfere with physical function as well as the quality of life of patients. In a collaborative effort, the iPROLEPSIS partners completed an initial extensive review, focusing on the state-of-the-art literature and existing datasets in the field of PsA, with a special focus on flare dynamics. The primary goal was to enhance the understanding of PsA by investigating disease symptoms, factors associated with flares, and markers for disease development and monitoring. The insights gained from the literature will provide background for various aspects of iPROLEPSIS research, such as investigating PsA inflammation drivers and monitoring, developing the iPROLEPSIS digital health ecosystem for personalised preventive care, and conducting clinical studies. Moreover, various multi-source datasets have been identified that can potentially yield valuable information for the discovery of PsA inflammation drivers and the development of novel digital biomarkers and predictive models for disease monitoring and progression prognosis. The identified datasets will be assessed for relevancy and usability, retrieved, harmonised and curated. These datasets and predictive models will contribute to the research on PsA monitoring and inflammation drivers. In addition, the identified existing datasets will also guide the development of the Lifestyle AI-driven recommendation system and the Serious Games. The key takeaways are: Fatigue, pain and stiffness are commonly reported symptoms in PsA Flare may be triggered by alterations in mood, stress, sleep, bowel movements, and environmental factors Flare may affect mood, stress, sleep, bowel movements, physical activity and fine motor skills Certain symptoms of PsA may also trigger or be triggered by flare Clinical measurements of PsA symptoms and hypothesized flare associated factors, mainly include questionnaires The use of smartphone and wearables to monitor physical activity (mainly through accelerometer data), fine motor skills (through keystroke dynamics), heart rate, heart rate variability have also shown potential to measure PsA symptoms and hypothesized flare associated factors Electrography techniques can also be used in the assessment of certain symptoms and flare associated factors Genetic factors may contribute to development of PsA, pain perception and response to treatment. Gut microbiome may be involved in PsA. MCs in skin are suggested to play a role in skin inflammation Monitoring of PsA can be achieved through clinical examination for inflamed joints, enthesitis dactylitis, nail and skin and subsequent calculation of relative indices and composite scores Imaging-based approaches including images obtained from smartphones and optoacoustics represent a complementary or alternative approach to clinical assessment Data-driven models can serve to find predictive relations even when the underlying mechanisms are poorly understood or are too complex. Recommendations and SGs present a potential approach to modify and improve diet and physical activity Besides diet and physical activity, SGs can also address other aspects of disease, including medication adherence, social support, cognition, breathing, biological and neural function OMOP CDM was opted to be used for standardising the datasets Future steps include an update on state-of-the-art literature and measurement tools on the topics covered by initial research and the identification of new datasets that could be relevant for data-driven models. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK Highlights from IFPA 2024 Jun 28, 2024 iPROLEPSIS at IFPA 2024 The 7th World Psoriasis & Psoriatic Arthritis Conference, held on June 27-29, 2024, brought together leading experts and researchers to discuss the latest advancements in psoriasis and psoriatic arthritis. Dr Laura Coates from the University of Oxford discussed the potential to prevent psoriatic arthritis, including the work being done in iPROLEPSIS and HIPPOCRATES IMI. 1/6 PREVIOUS NEXT